Breaking News Instant updates and real-time market news.

TEVA

Teva

$17.01

-0.64 (-3.63%)

, TWLO

Twilio

$85.24

-2.21 (-2.53%)

07:30
12/19/18
12/19
07:30
12/19/18
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Tuesday in Teva (TEVA), Twilio (TWLO), DowDuPont (DWDP), Carvana (CVNA), Brighthouse Financial (BHF), CarMax (KMX), and Virtu Financial (VIRT).

TEVA

Teva

$17.01

-0.64 (-3.63%)

TWLO

Twilio

$85.24

-2.21 (-2.53%)

DWDP

DowDuPont

$52.28

0.59 (1.14%)

CVNA

Carvana

$34.72

1.955 (5.97%)

BHF

Brighthouse Financial

$32.40

0.36 (1.12%)

KMX

CarMax

$59.78

-0.49 (-0.81%)

VIRT

Virtu Financial

$23.69

-1.12 (-4.51%)

  • 19

    Dec

  • 20

    Dec

  • 21

    Dec

  • 31

    Jan

  • 01

    Feb

TEVA Teva
$17.01

-0.64 (-3.63%)

11/14/18
JEFF
11/14/18
NO CHANGE
Target $21
JEFF
Hold
Teva management sees bottom of generic pricing cycle, says Jefferies
Teva believes that we are approaching the bottom of the generic drug pricing cycle, Jefferies analyst David Steinberg tells investors in a research note after meeting with the company's CEO and CFO in Israel. Management sees a flattening price erosion curve and does not expect that there will be further consolidation amongst buying consortiums, says the analyst. He adds that while the U.S. market will likely show little to no growth, Teva is focusing on international markets. Management believes long-term trends will allow single digit annual revenue growth for the next 20 years, writes Steinberg after the meeting. Further, the analyst points out Copaxone continues to erode at a slower rate than most observers expected and that Teva expects this to continue. He keeps a Hold rating on Teva shares with a $21 price target.
11/06/18
WELS
11/06/18
UPGRADE
Target $40
WELS
Outperform
Wells upgrades Mylan to Outperform, sees more upside after today's rally
Wells Fargo analyst David Maris upgraded Mylan (MYL) to Outperform from Market Perform with an unchanged price target of $40. The stock in afternoon trading is up 18%, or $5.76, to $37.13. Mylan shares have underperformed the S&P 500 Index for the year-to-date, one year, two year, and five year periods and the shares trade at a discount to peer Teva (TEVA), Maris tells investors in a research note titled "Concerns Abound, but Valuation Attractive." The analyst, however, believes Mylan is positioned for near-term outperformance after the company maintained its 2018 earnings guidance. Maris previously saw risk to second half of 2018 estimates, but with today's Q3 results, he now believes the risk to the downside to Q4 estimates is lower than previously thought. Further, Mylan's statement that Q4 guidance can be achieved with or without new approvals "provides some upside to sentiment" if generic Advair or other approvals materialize, says the analyst. Maris thinks that even with today's rally, Mylan shares still have more than 10% additional upside potential to reach fair value.
11/05/18
11/05/18
UPGRADE
Target $27

Overweight
Teva upgraded to Overweight on turnaround potential at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Teva to Overweight from Equal Weight, citing three main reasons. First, he expects strong cost cutting to drive earnings that top consensus forecasts. Second, he believes new products should deliver sales that top consensus forecasts. Third, he believes the market will assign Teva shares a higher multiple as the company executes and drives net debt /EBITDA down. Risinger, who noted that his adjusted EBITDA estimates for 2019-2020 are 6%-8% above consensus, raised his price target on Teva shares to $27 from $20.
11/05/18
MSCO
11/05/18
UPGRADE
MSCO
Overweight
Teva upgraded to Overweight from Equal Weight at Morgan Stanley
TWLO Twilio
$85.24

-2.21 (-2.53%)

12/18/18
DBAB
12/18/18
NO CHANGE
Target $110
DBAB
Buy
Twilio price target raised to $110 from $100 at Deutsche Bank
Deutsche Bank analyst Michael Turrin raised his price target for Twilio to $110 after examining the company's contact center software opportunity. He keeps a Buy rating on Twilio shares.
12/03/18
OPCO
12/03/18
NO CHANGE
OPCO
New Relic, VMware best positioned to benefit from secular shifts, says Oppenheimer
Oppenheimer analyst Ittai Kidron notes that he attended AWS' (AMZN) re:Invent user conference in Las Vegas, where he conducted a user survey giving him insight into application development and migration trends, the pace of DevOps adoption, forward IT spending intentions, and vendor positioning. Citing the survey, the analyst points out that DevOps practices are rapidly being adopted, and developers' prominence in IT budget/architecture decisions is driving market participants to offer end-to-end toolchains; hybrid/multi-cloud architectures are increasing in popularity, benefiting a select few providers; and legacy application migration activity is in early stages but set to gain momentum encompassing a broad range of applications. Within his coverage, Kidron sees New Relic (NEWR), Atlassian (TEAM), VMware (VMW) and Twilio (TWLO) as best positioned to benefit from secular shifts emphasizing the DevOps culture and adoption of hybrid/multi-cloud architectures.
11/23/18
OPCO
11/23/18
NO CHANGE
OPCO
Outperform
Twilio deal proxy suggests 'strong upside potential,' says Oppenheimer
Twilio (TWLO) on Wednesday filed a proxy in connection to its proposed acquisition of SendGrid (SEND), Oppenheimer analyst Ittai Kidron tells investors in a research note titled "SendGrid Proxy Reveals Strong Upside Potential." The analyst points out that Twilio made four cash offers for SendGrid before internal forecasts were shared and a stock deal was deemed as offering superior value. Further, Twilio's internal forecasts were materially above consensus calling for 136.3% net dollar expansion rate versus the consensus of 125.7%, says Kidron. SendGrid's projections were also well above consensus, he adds. Overall, Kidron continues to see "strong core business upside and compelling SendGrid deal rationale/synergies." He remains bullish on Twilio with an Outperform and $110 price target.
11/12/18
WBLR
11/12/18
NO CHANGE
WBLR
Outperform
William Blair still sees value in owning shares of Twilio
After taking a fresh look at Twilio's valuation following last week's post-earnings rally, William Blair analyst Bhavan Suri believes "there is still value in owning the stock." While the 35% rally on earnings "was probably a bit overdone," consensus expectations for 2019 and 2020 could prove conservative, Suri tells investors in a research note titled "Dreaming the Dream." The analyst says that if he were to assume Twilio can grow revenues 40% in 2019 and 30% in 2020, he would consider a cumulative growth rate of roughly 80% over the next two years. Applying an enterprise value of 10 times this forward revenue estimate, Suri says he would be able to justify a stock price of roughly $110. The analyst remains positive on Twilio's long-term fundamentals and thinks that "accumulating shares on any significant rationalization of the recent move makes sense." He keeps an Outperform rating on the name.
DWDP DowDuPont
$52.28

0.59 (1.14%)

11/05/18
SBSH
11/05/18
NO CHANGE
Target $67
SBSH
Buy
DowDuPont price target lowered to $67 from $74 at Citi
Citi analyst P.J. Juvekar lowered his price target for DowDuPont to $67 following the company's Q3 results but keeps a Buy rating on the shares. He lowered the target multiples applied to all three businesses to reflect lower valuations across comparable peers.
11/02/18
JPMS
11/02/18
NO CHANGE
Target $65
JPMS
Overweight
DowDuPont added to Analyst Focus List at JPMorgan
JPMorgan analyst Jeffrey Zekauskas added DowDuPont to his firm's Analyst Focus List following the company's Q3 results. DowDuPont is inexpensive on a sum-of-the-parts basis, Zekauskas tells investors in a research note. The analyst, who thought the company was conservatively worth $75 per share on a sum-of-the-parts basis in July, now thinks the shares are worth $65 in today's market as the values of comparable companies have fallen sharply through October. Zekauskas sees a "valuation discrepancy" at current share levels and keeps an Overweight rating on DowDuPont. The analyst lowered his price target for the stock to $65 from $75.
10/25/18
DBAB
10/25/18
NO CHANGE
DBAB
Deutsche Bank removes catalyst buy call on DowDuPont shares
Citing market volatility, Deutsche Bank analyst David Begleiter removed his "Catalyst Call" to buy shares of DowDuPont. The analyst, however, continues to like the stock on a 12-month basis due to the "value creation potential" of the three-way separation of the company in 2019.
12/04/18
FBCO
12/04/18
NO CHANGE
Target $113
FBCO
Outperform
FMC Corporation price target raised to $113 from $105 at Credit Suisse
Credit Suisse analyst Christopher Parkinson raised his price target for FMC Corporation (FMC) to $113 from $105 as he believes the company is making impressive strides to solidify itself within the "Big 5" alongside Bayer (BAYRY), Syngenta, BASF (BASFY) and DowDuPont (DWDP) post a large round of consolidation. The analyst reiterates an Outperform rating on the shares.
CVNA Carvana
$34.72

1.955 (5.97%)

12/07/18
WELS
12/07/18
NO CHANGE
Target $72
WELS
Outperform
Carvana long-term outlook intact, CarMax pilot 'a validation,' says Wells Fargo
Wells Fargo analyst Zachary Fadem attributed last week's volatility in Carvana (CVNA) shares to a lack of near-term catalysts coming out of its analyst day, investor concerns around Q4 volumes and the announcement that CarMax (KMX) is expanding its Omnichannel pilot in Atlanta. However, after hosting Carvana's VP of Investor Relations at the firm's Technology Summit, Fadem said he remains constructive on the long-term outlook and views the stock among the most compelling growth stories across his retail hardlines coverage. While CarMax's announcement "comes with understandable concern," Fadem views it as "a validation" of the Carvana model and sees Carvana's first mover advantage, customer-centric model and nation-wide network as competitive advantages. He maintains an Outperform rating and $72 price target on Carvana shares.
12/04/18
BARD
12/04/18
NO CHANGE
Target $68
BARD
Outperform
CarMax announcement doesn't change Baird's positive long-term view of Carvana
After CarMax (KMX) formally announced its omni-channel offering that was originally discussed in September, Baird analyst Colin Sebastian noted that the new service is similar to Carvana's (CVNA) e-commerce offering and he views it as an endorsement of Carvana's digital model. While the 10% slide in Carvana shares suggests significant concerns regarding the impact of CarMax's new offering, Sebastian believes that it is not a "winner take all market" and sees room in the $800B annual U.S. used car market for multiple players. Sebastian, who also said experience suggests many traditional retailers ultimately struggle to manage operating e-commerce and brick-and-mortar channels at the same time, has no change to his positive long-term view on Carvana and keeps an Outperform rating on the shares with a $68 price target.
12/07/18
SBSH
12/07/18
INITIATION
Target $55
SBSH
Buy
Carvana re-initiated with a Buy at Citi
Citi analyst Nicholas Jones re-initiated Carvana with a Buy rating and $55 price target.
12/07/18
SBSH
12/07/18
INITIATION
Target $70
SBSH
Buy
Citi calls Etsy and Carvana favorites in Specialty Internet
Citi analyst Nicholas Jones initiated coverage of both Etsy (ETSY) and Carvana (CVNA) with Buy ratings and price targets of $70 and $55, respectively. Carvana and Etsy are the analyst's favorites of the Specialty Internet companies.
BHF Brighthouse Financial
$32.40

0.36 (1.12%)

08/15/18
08/15/18
UPGRADE
Target $35

Neutral
Brighthouse Financial upgraded to Neutral as valuation should stabilize at Credit Suisse
As previously reported, Credit Suisse analyst Andrew Kligerman upgraded Brighthouse Financial to Neutral from Underperform, with a $35 price target. The analyst acknowledges the company could release capital and execute on its growth and expense reduction strategies, but still sees risk in itss variable annuity block. Since April, the stock has fallen more than 20%, but without near-term catalysts, Kligerman expects Brighthouse Financial's price to stabilize.
08/15/18
FBCO
08/15/18
UPGRADE
FBCO
Neutral
Brighthouse Financial upgraded to Neutral from Underperform at Credit Suisse
10/03/18
JPMS
10/03/18
NO CHANGE
JPMS
JPMorgan sees attractive risk/rewards for life insurance stocks
Life insurance stocks offer attractive risk/reward profiles at current share levels, JPMorgan analyst Jimmy Bhullar tells investors in a research note. The analyst, who's been cautious on the sector for the past two years, says that while his fundamental view "remains mixed," the macro environment has improved, investor sentiment has become negative, and valuation levels are more reasonable following the group's significant underperformance. He maintains Overweight ratings on Aflac (AFL), Lincoln National (LNC), and Prudential (PRU) and reiterates his negative stance on Brighthouse Financial (BHF).
10/03/18
BOFA
10/03/18
INITIATION
Target $47
BOFA
Neutral
Brighthouse Financial reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Ian Ryave reinstated Brighthouse Financial with a Neutral and $47 price target citing valuation.
KMX CarMax
$59.78

-0.49 (-0.81%)

12/04/18
CHLM
12/04/18
NO CHANGE
Target $40
CHLM
Hold
Carvana price target cut to $40 at Craig-Hallum after CarMax omni-channel news
After CarMax (KMX) announced a new omni-channel offering to allow consumers to buy a car completely from home, in-store or a combination, Craig-Hallum analyst Steve Dyer said he believes the hybrid brick-and-mortar and e-commerce platform could be the "ideal solution" for changing consumer demands. He also believes the news could put pressure on Carvana (CVNA) shares in the near-term. CarMax, which Dyer notes is the largest used vehicle retailer, is the latest competitor to increase focus on e-commerce following recent investments by Lithia (LAD) in Shift and AutoNation (AN) in Vroom, the analyst added. Dyer keeps a Hold rating on Carvana and lowered his price target on the stock to $40 from $48 to account for greater competitive threats.
12/14/18
WEDB
12/14/18
NO CHANGE
Target $87
WEDB
Outperform
Wedbush 'cautious' on CarMax into Q3 earnings
Wedbush analyst Seth Basham maintains an Outperform rating and $87 price target on CarMax, telling investors in a research note that he remains "cautious" into the company's Q3 earnings on December 21. Basham says he is "comfortable" with his comp forecast of -0.5%, well below consensus' +2.6%, and says that while buyside expectations are about in line with his forecast, he sees little to catalyze shares higher on the print.
VIRT Virtu Financial
$23.69

-1.12 (-4.51%)

08/08/18
08/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Optinose (OPTN) initiated with an Overweight at Cantor Fitzgerald. 2. BioCryst (BCRX) reinstated with an Overweight at JPMorgan. 3. Dillard's (DDS) initiated with an Outperform at Wedbush. 4. Virtu Financial (VIRT) initiated with an Equal Weight at Morgan Stanley. 5. Assembly Biosciences (ASMB) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/18
COMP
09/19/18
INITIATION
Target $23
COMP
Neutral
Virtu Financial initiated with a Neutral at Compass Point
Compass Point analyst Chris Allen initiated Virtu Financial with a Neutral and $23 price target saying the challenging operating environment in Q2 has carried over to Q3 and in most asset classes the environment has worsened.
09/19/18
09/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aerpio Pharmaceuticals (ARPO) initiated with a Buy at Guggenheim. 2. Vocera (VCRA) initiated with a Buy at Jefferies. 3. Veoneer (VNE) initiated with a Neutral at Buckingham. 4. Virtu Financial (VIRT) initiated with a Neutral at Compass Point. 5. Internap (INAP) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Neutral
Citi views potential ITG deal as favorable for Virtu Financial
A possible acquisition of Investment Technology Group (ITG) by Virtu Financial (VIRT), as reported yesterday by Bloomberg, points to "solid upside," Citi analyst Ben Herbert tell investors in a research note. The analyst views the potential deal favorably for Virtu given his belief that the company's standalone earnings growth may remain challenged against the current environment. His initial pass at potential deal accretion indicates $3.50 per share of upside for Virtu. Herbert keeps a Hold rating on Virtu shares.

TODAY'S FREE FLY STORIES

XLNX

Xilinx

$96.18

3.4 (3.66%)

, INTC

Intel

$52.06

0.95 (1.86%)

20:45
10/13/19
10/13
20:45
10/13/19
20:45
Upgrade
Xilinx, Intel rating change at Nomura Instinet »

Xilinx upgraded to Buy…

XLNX

Xilinx

$96.18

3.4 (3.66%)

INTC

Intel

$52.06

0.95 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 20

    Nov

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:49
10/13/19
10/13
19:49
10/13/19
19:49
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

FB

Facebook

$184.20

4.02 (2.23%)

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

T

AT&T

$37.58

0.17 (0.45%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

K

Kellogg

$62.14

-0.27 (-0.43%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

IGMS

IGM Biosciences

$17.53

-0.125 (-0.71%)

19:42
10/13/19
10/13
19:42
10/13/19
19:42
Initiation
IGM Biosciences initiated at Piper Jaffray »

IGM Biosciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37
Hot Stocks
LeMaitre acquires biologic patch business from Admedus »

LeMaitre Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

18:37
10/13/19
10/13
18:37
10/13/19
18:37
Periodicals
SoftBank seeking control of WeWork through financing package, WSJ says »

SoftBank (SFTBY) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

18:34
10/13/19
10/13
18:34
10/13/19
18:34
Hot Stocks
Kodiak Sciences announces safety, efficacy from Phase 1b study of KSI-301 »

Kodiak Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:29
10/13/19
10/13
18:29
10/13/19
18:29
Recommendations
Adverum Biotechnologies analyst commentary at Piper Jaffray »

Adverum '022 looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23
Hot Stocks
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022 »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$56.41

0.55 (0.98%)

18:03
10/13/19
10/13
18:03
10/13/19
18:03
Hot Stocks
ConocoPhillips announces $1.39B agreement to sell interests in Australia-West »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.58

0.17 (0.45%)

, CMCSA

Comcast

$45.53

1.02 (2.29%)

17:18
10/13/19
10/13
17:18
10/13/19
17:18
On The Fly
Box Office Battle: 'Joker' stays at number 1 with another $55M »

"Box Office Battle" is…

T

AT&T

$37.58

0.17 (0.45%)

CMCSA

Comcast

$45.53

1.02 (2.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$58.16

0.83 (1.45%)

LGF.A

Lionsgate

$9.52

0.22 (2.37%)

LGF.B

Lionsgate

$8.97

0.19 (2.16%)

DIS

Disney

$130.08

0.73 (0.56%)

VIAB

Viacom

$23.02

0.505 (2.24%)

VIA

Viacom

$25.45

0.65 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated at Wells Fargo »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

CNCE

Concert Pharmaceuticals

$5.85

(0.00%)

15:29
10/13/19
10/13
15:29
10/13/19
15:29
Hot Stocks
Concert Pharmaceuticals presents Phase 2 data in Alopecia Areata »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$76.14

0.38 (0.50%)

15:23
10/13/19
10/13
15:23
10/13/19
15:23
Hot Stocks
Incyte announces 52-week results from Phase 2 study of Ruxolitinib cream »

Incyte announced 52-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.